NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $20.60 -0.15 (-0.72%) (As of 02:37 PM ET) Add Compare Share Share Today's Range$20.11▼$21.4150-Day Range$18.08▼$25.3852-Week Range$17.52▼$45.00Volume172,543 shsAverage Volume492,889 shsMarket Capitalization$554.80 millionP/E RatioN/ADividend YieldN/APrice Target$71.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside246.6% Upside$71.40 Price TargetShort InterestBearish21.78% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.81Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.60) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector585th out of 927 stocksPharmaceutical Preparations Industry272nd out of 425 stocks 3.6 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.78% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 1.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth.Dividend SustainabilityBased on EPS estimates, Arcturus Therapeutics will have a dividend payout ratio of 357.50% in the coming year. This indicates that Arcturus Therapeutics may not be able to sustain their current dividend.Read more about Arcturus Therapeutics' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 3.2 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search Interest9 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.60) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesSeptember 16 at 4:27 AM | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Buy" by BrokeragesSeptember 15 at 7:46 PM | markets.businessinsider.comBuy Rating Justified by Arcturus Therapeutics’s Vaccine Advancements and Market Expansion PotentialSeptember 16, 2024 | DTI (Ad)Fear of an impending recessionA lot of traders are worried about the threat of a recession… and with good reason. How can you guard against the worst case scenario? Use a tool that could see this collapse coming… Like my 10 AM Income Project. Back in July, the trading tool behind this 10 AM Income Project fired a serious warning signal… Even though NVDA was firing on all cylinders and every stock trader in the world seemed to want a piece, I saw the “red flag” because of these two lines…September 13 at 4:37 PM | markets.businessinsider.comCSL And Arcturus Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 VaccineSeptember 13 at 4:37 PM | markets.businessinsider.comArcturus Therapeutics: Strong Buy Rating on Promising Vaccine Distribution and Advancements in Rare Disease TreatmentsSeptember 13 at 8:15 AM | prnewswire.comJapan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaSeptember 13 at 1:55 AM | uk.finance.yahoo.comTop High Growth Tech Stocks to Watch in September 2024September 11, 2024 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Rating Reiterated by Cantor FitzgeraldSeptember 16, 2024 | DTI (Ad)Fear of an impending recessionA lot of traders are worried about the threat of a recession… and with good reason. How can you guard against the worst case scenario? Use a tool that could see this collapse coming… Like my 10 AM Income Project. Back in July, the trading tool behind this 10 AM Income Project fired a serious warning signal… Even though NVDA was firing on all cylinders and every stock trader in the world seemed to want a piece, I saw the “red flag” because of these two lines…September 8, 2024 | msn.comArcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short SellersSeptember 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Arcturus Therapeutics’ Promising Cystic Fibrosis Program ProgressAugust 22, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Soleno Therapeutics (SLNO)August 17, 2024 | finance.yahoo.comARCT Mar 2025 25.000 call (ARCT250321C00025000)August 13, 2024 | msn.comLeerink Partners Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Outperform RecommendationAugust 9, 2024 | seekingalpha.comHigh-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive VaccineAugust 7, 2024 | markets.businessinsider.comArcturus Therapeutics: Buy Rating Affirmed Amid Kostaive Launch and ARCT-810 Clinical AdvancementsAugust 7, 2024 | finance.yahoo.comArcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline ProgressAugust 6, 2024 | insidermonkey.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2024 Earnings Call TranscriptSee More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/16/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$71.40 High Stock Price Target$90.00 Low Stock Price Target$48.00 Potential Upside/Downside+244.1%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-41.21% Pretax Margin-42.27% Return on Equity-25.47% Return on Assets-16.25% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.78 Sales & Book Value Annual Sales$169.93 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book1.99Miscellaneous Outstanding Shares26,930,000Free Float23,215,000Market Cap$558.80 million OptionableOptionable Beta2.60 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MDr. Padmanabh Chivukula Ph.D. (Age 45)Founder, Chief Scientific Officer, COO & Secretary Comp: $787.5kMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerJoseph RobertsControllerMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCStoke TherapeuticsNASDAQ:STOKMersana TherapeuticsNASDAQ:MRSNShattuck LabsNASDAQ:STTKNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 91,224 shares on 8/19/2024Ownership: 0.907%Deerfield Management Company L.P. Series CBought 39,328 shares on 8/15/2024Ownership: 0.146%Scientech Research LLCBought 15,377 shares on 8/15/2024Ownership: 0.057%AQR Capital Management LLCSold 62,525 shares on 8/15/2024Ownership: 0.043%Point72 Asia Singapore Pte. Ltd.Bought 5,852 shares on 8/15/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of 2024. Since then, ARCT shares have decreased by 34.7% and is now trading at $20.60. View the best growth stocks for 2024 here. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings results on Monday, August, 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($1.85) by $1.21. The biotechnology company had revenue of $49.86 million for the quarter, compared to analyst estimates of $21 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative trailing twelve-month return on equity of 25.47%. When did Arcturus Therapeutics' stock split? Arcturus Therapeutics's stock split on Saturday, January 1st 2000. The 7-1 split was announced on Saturday, January 1st 2000. The newly issued shares were payable to shareholders after the market closes on Thursday, November 16th 2017. An investor that had 100 shares of stock prior to the split would have 700 shares after the split. Who are Arcturus Therapeutics' major shareholders? Top institutional investors of Arcturus Therapeutics include Federated Hermes Inc. (17.43%), ARK Investment Management LLC (7.30%), Sumitomo Mitsui Trust Holdings Inc. (5.80%) and Dimensional Fund Advisors LP (3.41%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK) and NVIDIA (NVDA). This page (NASDAQ:ARCT) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts